Results 111 to 120 of about 276,656 (346)

Altering retinol binding protein 4 levels in hepatitis C: Inflammation and steatosis matter

Virulence, 2020
Both hepatitis C virus (HCV) infection and retinol-binding protein 4 (RBP4) might contribute to insulin resistance (IR), how RBP4 links to IR in HCV infection remain elusive.
Ming-Ling Chang, Wei-Ting Chen, Jing-Hong Hu, Shiang-Chi Chen, Po-Wen Gu, Rong-Nan Chien   +5 more
doaj   +1 more source

The prevalence of positive rapid diagnostic test of hepatitis C virus infection in Ghana

The Pan African Medical Journal, 2020
INTRODUCTION: HCV infection is one of the most common viral hepatitis in Africa. Rapid diagnostic test (RDT) is a useful tool to identify antibody anti-HCV in point of care.
Masood Maleki Birjandi, Mahbobeh Oroei
doaj   +1 more source

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.

Gastroenterology, 2015
BACKGROUND & AIMS Patients with detectable hepatitis C virus (HCV) RNA at the time of liver transplantation universally experience recurrent HCV infection.
Michael P. Curry, X. Forns, Raymond T. Chung, N. Terrault, Robert S. Brown, J. Fenkel, F. Gordon, O. Jacqueline, Leary, A. Kuo, T. Schiano, G. Everson, E. Schiff, A. Befeler, E. Gane, S. Saab, J. Mchutchison, G. Subramanian, W. Symonds, J. Denning, L. Mcnair, S. Arterburn, E. Svarovskaia, D. Moonka, N. Afdhal   +24 more
semanticscholar   +1 more source

Promising Prodiginins Biological Activities

Chemistry &Biodiversity, EarlyView.
ABSTRACT Prodiginins are a large family of at least 34 pyrrolic compounds, including the well‐studied red pigment prodigiosin. Prodiginins are produced by several microorganisms displaying broad biological activities, including antimicrobial, antiviral, antiparasitic, antiproliferative, and immunosuppressive activities.
María F. Ladetto, Melisa E. Gantner, Boris E. Rodenak‐Kladniew, Santiago Rodriguez, María L. Cuestas, Alan Talevi, Guillermo R. Castro   +6 more
wiley   +1 more source

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).

Clinical Infectious Diseases, 2016
BACKGROUND Shortening the duration of treatment with HCV direct-acting antivirals (DAAs) leads to substantial cost reductions. According to the label, sofosbuvir and ledipasvir can be prescribed for 8 weeks (SL8) in noncirrhotic women or men with HCV ...
P. Ingiliz, S. Christensen, Torben Kimhofer, D. Hueppe, T. Lutz, K. Schewe, H. Busch, G. Schmutz, M. Wehmeyer, C. Boesecke, K. Simon, F. Berger, J. Rockstroh, J. Schulze zur Wiesch, A. Baumgarten, S. Mauss   +15 more
semanticscholar   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open‐Label, Phase I Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Valemetostat tosylate (valemetostat) is a dual inhibitor of enhancer of zeste homolog (EZH) 2 and EZH1, approved in Japan for the treatment of relapsed/refractory peripheral T‐cell lymphoma and adult T‐cell leukemia/lymphoma. This Phase I, open‐label study evaluated the pharmacokinetics and safety of a single 50‐mg oral dose of valemetostat in
Masaya Tachibana, Thuy Vu Craveiro, Thomas C. Marbury, Samuel Oberstein, George J. Atiee, Ben Tao, Takako Shimizu, Yvonne Lau, Malaz A. Abutarif   +8 more
wiley   +1 more source

Priming persistence of HCV

Oncotarget, 2015
Acute infection with hepatitis C virus (HCV) is cleared in about 30% of cases with CD8+ T-cells being the main effector cells in viral elimination. Yet, about 70% of patients progress to chronic HCV infection that can result in chronic immunopathology. This immune-mediated liver diseases can progress to liver cirrhosis and ultimately to hepatocellular ...
Schuch, Anita, Thimme, Robert, Hofmann, Maike   +2 more
openaire   +4 more sources

Acute myocarditis according to age: Presentation, management and early outcomes

ESC Heart Failure, EarlyView.
MIS, multisystem inflammatory syndrome; MRE, myocarditis‐related events (within 30 days included all‐cause death, cardiogenic shock, cardiac arrest, ventricular arrhythmias or complete AV block). Abstract Aims Acute myocarditis (AM) is a rare but severe disease affecting patients of all ages. Large multicentric studies comparing children and adults are
Clément Karsenty, Paul Vignaud, Clara Brusq, Pamela Moceri, Pascal Lim, Edouard Gerbaud, Olivier Lairez, Coline Lelarge, Caroline Ovaert, Claire Bouleti, Oscar Werner, Vanina Bongard, Thibaud Genet, Laurent Bonnemains, Christophe Tron, Elise Barre, Margaux Boddaert, Jacques Mansourati, Chérine Benzouid, François Roubille, Hadi Khachab, Sabrina Uhry, Ariel Cohen, Benoit Lattuca, Sylvie Di Filippo, Clément Delmas   +25 more
wiley   +1 more source

Exploring the Potential and Advancements of Circular RNA Therapeutics

Exploration, EarlyView.
Given the remarkable advantages in terms of stability, sustained expression profile, safety, wide range of druggable targets, scalable and cost‐effective manufacturing capabilities, circRNA is currently undergoing intensive investigation for various therapeutic applications such as vaccines, protein replacement, genetic disease treatment, gene therapy,
Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu   +6 more
wiley   +1 more source